A number of contributing factors have been identified in TH-MYCN tumor initiation such as p53 deregulation, metabolic adaptation, micro-RNA deregulation and the MYCN binding proteome, many of which represent promising therapeutic targets in MYCN-driven neuroblastoma [10,13,14,15,16,17,18,19,20,21]. The gene discussed is MYCN; the disease is neuroblastoma.